Biopharma company Otonomy receives $49.5m series C from numerous backers, including university investment consortium Osage University Partners.
Otonomy, a US-based pharmaceutical company, has raised $49.5m in a series C round backed by university investment consortium Osage University Partners. The round was led by OrbiMed Advisors, with Aperture Venture Partners and Osage as new investors. Existing investors Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech also participated. Otonomy, founded…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
